Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T21:29:03.275Z.
Calculation as of: 2026-10-06T21:29:03.275Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 05c00b329f1e3adc6cfa9751fac96b44e9956e0cda8839801cbe896438e656e1
PEG RATIO
N/A
Market Cap
$1.59B
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.49B
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.48B
PEG Ratio
1.18
TTM Avg
2.73
3Y Avg
2.90
5Y Avg
2.90
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Syndax Pharmaceuticals, Inc. (SNDX) | $1.54B | N/A | N/A | N/A | N/A |
| Innoviva, Inc. (INVA)vs › | $1.54B | 0.49 | 0.51 | 1.07 | 0.57 |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | N/A | N/A | N/A | N/A |
| Nutex Health, Inc. (NUTX)vs › | $1.50B | N/A | 0.13 | 0.13 | 0.13 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | N/A | N/A | N/A | N/A |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | N/A | N/A | N/A | N/A |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.49B | N/A | N/A | N/A | N/A |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 1.18 | 2.73 | 2.90 | 2.90 |
| uniQure N.V. (QURE)vs › | $1.60B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.48B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
